跳转至内容
Merck
CN
  • Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Digestive diseases and sciences (2014-09-23)
Javier P Gisbert, Jesús Barrio, Inés Modolell, Javier Molina-Infante, Angeles Perez Aisa, Manuel Castro-Fernández, Luis Rodrigo, Angel Cosme, Jose Luis Gisbert, Miguel Fernández-Bermejo, Santiago Marcos, Alicia C Marín, Adrián G McNicholl
摘要

Helicobacter pylori eradication is a challenge in penicillin allergy. To assess the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin. Prospective multicenter study. Patients allergic to penicillin were given a first-line treatment comprising (a) 7-day omeprazole-clarithromycin-metronidazole and (b) 10-day omeprazole-bismuth-tetracycline-metronidazole. Rescue treatments were as follows: (a) bismuth quadruple therapy; (b) 10-day PPI-clarithromycin-levofloxacin; and (c) 10-day PPI-clarithromycin-rifabutin. Eradication was confirmed by (13)C-urea breath test. Compliance was determined through questioning and recovery of empty medication envelopes. Adverse effects were evaluated by questionnaires. In total, 267 consecutive treatments were included. (1) First-line treatment: Per-protocol and intention-to-treat eradication rates with omeprazole-clarithromycin-metronidazole were 59 % (62/105; 95 % CI 49-62 %) and 57 % (64/112; 95 % CI 47-67 %). Respective figures for PPI-bismuth-tetracycline-metronidazole were 75 % (37/49; 95 % CI 62-89 %) and 74 % (37/50; 95 % CI (61-87 %) (p < 0.05). Compliance with treatment was 94 and 98 %, respectively. Adverse events were reported in 14 % with both regimens (all mild). (2) Second-line treatment: Intention-to-treat eradication rate with omeprazole-clarithromycin-levofloxacin was 64 % both after triple and quadruple failure; compliance was 88-100 %, with 23-29 % adverse effects (all mild). (3) Third-/fourth-line treatment: Intention-to-treat eradication rate with PPI-clarithromycin-rifabutin was 22 %. In allergic to penicillin patients, a first-line treatment with a bismuth-containing quadruple therapy (PPI-bismuth-tetracycline-metronidazole) seems to be a better option than the triple PPI-clarithromycin-metronidazole regimen. A levofloxacin-based regimen (together with a PPI and clarithromycin) represents a second-line rescue option in the presence of penicillin allergy.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
四环素, 98.0-102.0% (HPLC)
Sigma-Aldrich
甲硝唑, BioXtra
Sigma-Aldrich
左氧氟沙星, 98.0-102.0% anhydrous basis (HPLC)
Supelco
奥美拉唑, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
甲硝唑, analytical standard
Supelco
甲硝唑, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
铋, powder, −100 mesh, 99% trace metals basis
Sigma-Aldrich
奥美拉唑, solid
Supelco
克拉霉素, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
克拉霉素, ≥95% (HPLC)
Sigma-Aldrich
铋, powder, −100 mesh, ≥99.99% trace metals basis
Supelco
左氧氟沙星, analytical standard
Sigma-Aldrich
铋, pieces, 1-12 mm, 99.999% trace metals basis
USP
奥美拉唑, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
克拉霉素, 96.0-102.0% (HPLC)
Sigma-Aldrich
Rifabutin, >98% (HPLC), powder
USP
克拉霉素, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
铋, shot, 4-30 mesh, 99.9% trace metals basis
USP
Rifabutin, United States Pharmacopeia (USP) Reference Standard
Supelco
甲硝唑, VETRANAL®, analytical standard
Rifabutin, European Pharmacopoeia (EP) Reference Standard
Supelco
奥美拉唑, analytical standard
奥美拉唑, European Pharmacopoeia (EP) Reference Standard
克拉霉素, European Pharmacopoeia (EP) Reference Standard
奥美拉唑, European Pharmacopoeia (EP) Reference Standard
甲硝唑, European Pharmacopoeia (EP) Reference Standard
克拉霉素, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
铋, beads, 1-5 mm, 99.999% trace metals basis
铋, foil, not light tested, 50x50mm, thickness 0.01mm, permanent polyester support, 99.97%
铋, foil, 25x25mm, thickness 0.25mm, 100%